Teleflex Incorporated (NYSE:TFX - Get Free Report) was the recipient of a large increase in short interest during the month of September. As of September 30th, there was short interest totaling 1,840,000 shares, an increase of 42.6% from the September 15th total of 1,290,000 shares. Currently, 4.2% of the shares of the company are short sold. Based on an average trading volume of 591,500 shares, the short-interest ratio is currently 3.1 days. Based on an average trading volume of 591,500 shares, the short-interest ratio is currently 3.1 days. Currently, 4.2% of the shares of the company are short sold.
Analysts Set New Price Targets
A number of research firms have weighed in on TFX. Wall Street Zen lowered shares of Teleflex from a "strong-buy" rating to a "buy" rating in a research report on Monday, September 15th. Weiss Ratings reaffirmed a "sell (d+)" rating on shares of Teleflex in a research report on Wednesday, October 8th. Royal Bank Of Canada increased their price target on shares of Teleflex from $130.00 to $135.00 and gave the stock a "sector perform" rating in a research report on Friday, August 1st. Wells Fargo & Company dropped their price target on shares of Teleflex from $137.00 to $131.00 and set an "equal weight" rating for the company in a research report on Friday, August 1st. Finally, Mizuho increased their price target on shares of Teleflex from $130.00 to $135.00 and gave the stock a "neutral" rating in a research report on Friday, August 1st. One equities research analyst has rated the stock with a Buy rating, nine have given a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat, Teleflex presently has an average rating of "Reduce" and an average target price of $141.57.
Read Our Latest Analysis on Teleflex
Teleflex Price Performance
Teleflex stock traded down $1.01 during trading hours on Thursday, hitting $131.78. 89,284 shares of the stock were exchanged, compared to its average volume of 743,011. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.44 and a current ratio of 2.41. The stock has a market capitalization of $5.82 billion, a P/E ratio of 31.01, a P/E/G ratio of 1.86 and a beta of 1.05. Teleflex has a 12 month low of $108.90 and a 12 month high of $239.46. The business's 50-day moving average is $125.85 and its two-hundred day moving average is $123.64.
Teleflex (NYSE:TFX - Get Free Report) last issued its quarterly earnings data on Thursday, July 31st. The medical technology company reported $3.73 earnings per share for the quarter, topping the consensus estimate of $3.36 by $0.37. The firm had revenue of $780.90 million for the quarter, compared to analysts' expectations of $771.53 million. Teleflex had a net margin of 6.31% and a return on equity of 15.08%. The company's quarterly revenue was up 4.2% compared to the same quarter last year. During the same period in the prior year, the firm earned $3.42 earnings per share. Teleflex has set its FY 2025 guidance at 13.900-14.300 EPS. Equities research analysts expect that Teleflex will post 13.98 EPS for the current fiscal year.
Teleflex Announces Dividend
The company also recently disclosed a quarterly dividend, which was paid on Monday, September 15th. Shareholders of record on Friday, August 15th were paid a dividend of $0.34 per share. This represents a $1.36 annualized dividend and a yield of 1.0%. The ex-dividend date of this dividend was Friday, August 15th. Teleflex's dividend payout ratio is currently 32.00%.
Insider Activity
In other news, CEO Liam Kelly bought 1,500 shares of the business's stock in a transaction on Tuesday, August 5th. The stock was purchased at an average price of $115.07 per share, with a total value of $172,605.00. Following the transaction, the chief executive officer directly owned 45,267 shares in the company, valued at approximately $5,208,873.69. The trade was a 3.43% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Gretchen R. Haggerty bought 500 shares of the business's stock in a transaction on Wednesday, August 6th. The shares were purchased at an average cost of $114.75 per share, with a total value of $57,375.00. Following the transaction, the director owned 6,305 shares in the company, valued at approximately $723,498.75. The trade was a 8.61% increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last 90 days, insiders have acquired 5,500 shares of company stock worth $633,590. Insiders own 1.40% of the company's stock.
Institutional Trading of Teleflex
Large investors have recently added to or reduced their stakes in the company. Teacher Retirement System of Texas bought a new stake in Teleflex during the first quarter worth about $1,242,000. Amalgamated Bank grew its stake in shares of Teleflex by 56.9% during the first quarter. Amalgamated Bank now owns 14,046 shares of the medical technology company's stock valued at $1,941,000 after purchasing an additional 5,095 shares during the last quarter. New York State Teachers Retirement System grew its stake in shares of Teleflex by 13.9% during the first quarter. New York State Teachers Retirement System now owns 45,063 shares of the medical technology company's stock valued at $6,227,000 after purchasing an additional 5,482 shares during the last quarter. NorthCrest Asset Manangement LLC bought a new stake in shares of Teleflex during the second quarter valued at approximately $299,000. Finally, Brown Advisory Inc. grew its stake in shares of Teleflex by 34.2% during the first quarter. Brown Advisory Inc. now owns 2,524 shares of the medical technology company's stock valued at $349,000 after purchasing an additional 643 shares during the last quarter. 95.62% of the stock is owned by institutional investors.
Teleflex Company Profile
(
Get Free Report)
Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. The company provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Teleflex, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Teleflex wasn't on the list.
While Teleflex currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report